Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Lilly's Verzenio has failed to show benefits in lung ... A total of 453 patients were randomised to receive 200 mg of abemaciclib orally twice a day on a continuous dosing schedule, every 12 ...